Quantitative analysis of survivin protein expression and its therapeutic depletion by an antisense oligonucleotide in human lung tumors

Molecular Therapy Nucleic Acids

Volumn 1, Issue 6, 2012, Pages e30-

  Olsen, Anna L ^a   Davies, Joanne M ^b   Medley, Louise ^b   Breen, David ^c   Talbot, Denis C ^b   McHugh, Peter J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Antisense therapy; Lung cancer; Survivin

Indexed keywords

EID: 84868383175     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2012.19     Document Type: Article

References (48)

1. Rayburn, ER and Zhang, R (2008). Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? Drug Discov Today 13: 513-521.
2. Castanotto, D and Rossi, JJ (2009). The promises and pitfalls of RNA-interference-based therapeutics. Nature 457: 426-433.
3. Chi, KN, Eisenhauer, E, Fazli, L, Jones, EC, Goldenberg, SL, Powers, J et al. (2005). A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 97: 1287-1296. (Pubitemid 41535369)
4. Lai, SY, Koppikar, P, Thomas, SM, Childs, EE, Egloff, AM, Seethala, RR et al. (2009). Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms. J Clin Oncol 27: 1235-1242.
5. Leong, AS and Leong, TY (2006). Newer developments in immunohistology. J Clin Pathol 59: 1117-1126. (Pubitemid 44787131)
6. Taylor, CR and Levenson, RM (2006). Quantification of immunohistochemistry-issues concerning methods, utility and semiquantitative assessment II. Histopathology 49: 411-424. (Pubitemid 44401549)
7. Walker, RA (2006). Quantification of immunohistochemistry-issues concerning methods, utility and semiquantitative assessment I. Histopathology 49: 406-410. (Pubitemid 44401548)
8. Moulder, SL, Symmans, WF, Booser, DJ, Madden, TL, Lipsanen, C, Yuan, L et al. (2008). Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Clin Cancer Res 14: 7909-7916.
9. Liu, G, Kolesar, J, McNeel, DG, Leith, C, Schell, K, Eickhoff, J et al. (2008). A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors. Clin Cancer Res 14: 2732-2739.
10. Plummer, R, Vidal, L, Griffin, M, Lesley, M, de Bono, J, Coulthard, S et al. (2009). Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors. Clin Cancer Res 15: 3177-3183.
11. Shibata, SI, Doroshow, JH, Frankel, P, Synold, TW, Yen, Y, Gandara, DR et al. (2009). Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study. Cancer Chemother Pharmacol 64: 1149-1155.
12. Chi, KN, Siu, LL, Hirte, H, Hotte, SJ, Knox, J, Kollmansberger, C et al. (2008). A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 14: 833-839. (Pubitemid 351231167)
13. Dritschilo, A, Huang, CH, Rudin, CM, Marshall, J, Collins, B, Dul, JL et al. (2006). Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. Clin Cancer Res 12: 1251-1259. (Pubitemid 43342516)
14. O'Dwyer, PJ, Stevenson, JP, Gallagher, M, Cassella, A, Vasilevskaya, I, Monia, BP et al. (1999). c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A). Clin Cancer Res 5: 3977-3982. (Pubitemid 30013773)
15. Rudin, CM, Marshall, JL, Huang, CH, Kindler, HL, Zhang, C, Kumar, D et al. (2004). Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. Clin Cancer Res 10: 7244-7251. (Pubitemid 39487711)
16. Stewart, DJ, Donehower, RC, Eisenhauer, EA, Wainman, N, Shah, AK, Bonfils, C et al. (2003). A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly. Ann Oncol 14: 766-774. (Pubitemid 36621778)
17. Rudin, CM, Holmlund, J, Fleming, GF, Mani, S, Stadler, WM, Schumm, P et al. (2001). Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin Cancer Res 7: 1214-1220. (Pubitemid 32708672)
18. Nishizuka, S, Charboneau, L, Young, L, Major, S, Reinhold, WC, Waltham, M et al. (2003). Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci USA 100: 14229-14234. (Pubitemid 37499219)
19. Chen, G, Gharib, TG, Huang, CC, Taylor, JM, Misek, DE, Kardia, SL et al. (2002). Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 1: 304-313.
20. Greenbaum, D, Colangelo, C, Williams, K and Gerstein, M (2003). Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol 4: 117.
21. Feng, Y, Mitchison, TJ, Bender, A, Young, DW and Tallarico, JA (2009). Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds. Nat Rev Drug Discov 8: 567-578.
22. Ambrosini, G, Adida, C and Altieri, DC (1997). A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921. (Pubitemid 27353455)
23. Tamm, I, Wang, Y, Sausville, E, Scudiero, DA, Vigna, N, Oltersdorf, T et al. (1998). IAPfamily protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58: 5315-5320. (Pubitemid 28551107)
24. Deveraux, QL and Reed, JC (1999). IAP family proteins-suppressors of apoptosis. Genes Dev 13: 239-252.
25. Verdecia, MA, Huang, H, Dutil, E, Kaiser, DA, Hunter, T and Noel, JP (2000). Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat Struct Biol 7: 602-608. (Pubitemid 30445919)
26. Uren, AG, Wong, L, Pakusch, M, Fowler, KJ, Burrows, FJ, Vaux, DL et al. (2000). Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol 10: 1319-1328.
27. Li, F, Ambrosini, G, Chu, EY, Plescia, J, Tognin, S, Marchisio, PC et al. (1998). Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396: 580-584. (Pubitemid 28563719)
28. Li, F, Ackermann, EJ, Bennett, CF, Rothermel, AL, Plescia, J, Tognin, S et al. (1999). Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1: 461-466. (Pubitemid 129503664)
29. Lens, SM, Wolthuis, RM, Klompmaker, R, Kauw, J, Agami, R, Brummelkamp, T et al. (2003). Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J 22: 2934-2947. (Pubitemid 36758615)
30. Carvalho, A, Carmena, M, Sambade, C, Earnshaw, WC and Wheatley, SP (2003). Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J Cell Sci 116(Pt 14): 2987-2998. (Pubitemid 36926987)
31. Altieri, DC (2008). New wirings in the survivin networks. Oncogene 27: 6276-6284.
32. Altieri, DC (2008). Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8: 61-70.
33. Fukuda, S and Pelus, LM (2006). Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 5: 1087-1098. (Pubitemid 43881300)
34. Altieri, DC (2003). Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3: 46-54. (Pubitemid 37328886)
35. Tran, J, Master, Z, Yu, JL, Rak, J, Dumont, DJ and Kerbel, RS (2002). A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 99: 4349-4354. (Pubitemid 34285988)
36. Morgillo, F, Woo, JK, Kim, ES, Hong, WK and Lee, HY (2006). Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 66: 10100-10111. (Pubitemid 44672064)
37. Carrasco, RA, Stamm, NB, Marcusson, E, Sandusky, G, Iversen, P and Patel, BK (2011). Antisense inhibition of survivin expression as a cancer therapeutic. Mol Cancer Ther 10: 221-232.
38. Ruchaud, S, Carmena, M and Earnshaw, WC (2007). Chromosomal passengers: conducting cell division. Nat Rev Mol Cell Biol 8: 798-812. (Pubitemid 47462135)
39. Chen, J, Jin, S, Tahir, SK, Zhang, H, Liu, X, Sarthy, AV et al. (2003). Survivin enhances Aurora- B kinase activity and localizes Aurora-B in human cells. J Biol Chem 278: 486-490. (Pubitemid 36043600)
40. Ottesen, GL, Christensen, IJ, Larsen, JK, Hansen, B and Andersen, JA (1996). Tissue disaggregation for flow cytometric DNA analysis: comparison of fine-needle aspiration and an automated mechanical procedure. Cytometry 26: 65-68. (Pubitemid 26110014)
41. Merkel, DE, Dressler, LG and McGuire, WL (1987). Flow cytometry, cellular DNA content, and prognosis in human malignancy. J Clin Oncol 5: 1690-1703.
42. McLean, AN, Semple, PA, Franklin, DH, Petrie, G, Millar, EA and Douglas, JG (1998). The Scottish multi-centre prospective study of bronchoscopy for bronchial carcinoma and suggested audit standards. Respir Med 92: 1110-1115. (Pubitemid 28454339)
43. Aviel-Ronen, S, Blackhall, FH, Shepherd, FA and Tsao, MS (2006). K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer 8: 30-38. (Pubitemid 44336241)
44. Coate, LE, John, T, Tsao, MS and Shepherd, FA (2009). Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol 10: 1001-1010.
45. Hirsch, FR, Varella-Garcia, M and Cappuzzo, F (2009). Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene 28 (suppl. 1): S32-S37.
46. Vilmar, A and Sørensen, JB (2009). Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer 64: 131-139.
47. Talbot, DC, Ranson, M, Davies, J, Lahn, M, Callies, S, André, V et al. (2010). Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. Clin Cancer Res 16: 6150-6158.
48. Vindeløv, LL and Christensen, IJ (1990). A review of techniques and results obtained in one laboratory by an integrated system of methods designed for routine clinical flow cytometric DNA analysis. Cytometry 11: 753-770. (Pubitemid 20303041)